Amyloid-Journal of Protein Folding Disorders

Papers
(The H4-Index of Amyloid-Journal of Protein Folding Disorders is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Amyloid nomenclature 2020: update and recommendations by the International Society of Amyloidosis (ISA) nomenclature committee263
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee100
Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial98
Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis55
ATTRv amyloidosis Italian Registry: clinical and epidemiological data51
Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis47
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines42
Arterial thrombo-embolic events in cardiac amyloidosis: a look beyond atrial fibrillation39
Anticoagulation with warfarin compared to novel oral anticoagulants for atrial fibrillation in adults with transthyretin cardiac amyloidosis: comparison of thromboembolic events and major bleeding30
Neurofilament light chain, a biomarker for polyneuropathy in systemic amyloidosis29
Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen25
Association between spinal stenosis and wild-type ATTR amyloidosis25
Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging23
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma23
Protease resistance of ex vivo amyloid fibrils implies the proteolytic selection of disease-associated fibril morphologies23
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group22
Tissue biopsy for the diagnosis of amyloidosis: experience from some centres22
Next generation flow cytometry for MRD detection in patients with AL amyloidosis21
TTR gene silencing therapy in post liver transplant hereditary ATTR amyloidosis patients19
0.018929004669189